453 related articles for article (PubMed ID: 18318765)
1. Rituximab in the treatment of autoimmune haematological disorders.
Garvey B
Br J Haematol; 2008 Apr; 141(2):149-69. PubMed ID: 18318765
[TBL] [Abstract][Full Text] [Related]
2. B-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
Zaja F; Iacona I; Masolini P; Russo D; Sperotto A; Prosdocimo S; Patriarca F; de Vita S; Regazzi M; Baccarani M; Fanin R
Haematologica; 2002 Feb; 87(2):189-95. PubMed ID: 11836170
[TBL] [Abstract][Full Text] [Related]
3. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
[TBL] [Abstract][Full Text] [Related]
4. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
5. New treatment options for immune-mediated hematological disorders.
Dierickx D; De Rycke A; Vanderschueren S; Delannoy A
Eur J Intern Med; 2008 Dec; 19(8):579-86. PubMed ID: 19046722
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy for autoimmune haematological diseases.
Barcellini W; Zanella A
Eur J Intern Med; 2011 Jun; 22(3):220-9. PubMed ID: 21570637
[TBL] [Abstract][Full Text] [Related]
7. Rituximab in the treatment of refractory autoimmune cytopenias in adults.
Narat S; Gandla J; Hoffbrand AV; Hughes RG; Mehta AB
Haematologica; 2005 Sep; 90(9):1273-4. PubMed ID: 16154853
[TBL] [Abstract][Full Text] [Related]
8. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibodies in the treatment of autoimmune cytopenias.
Robak T
Eur J Haematol; 2004 Feb; 72(2):79-88. PubMed ID: 14962245
[TBL] [Abstract][Full Text] [Related]
10. Rituximab therapy for chronic lymphocytic leukemia-associated autoimmune hemolytic anemia.
D'Arena G; Laurenti L; Capalbo S; D'Arco AM; De Filippi R; Marcacci G; Di Renzo N; Storti S; Califano C; Vigliotti ML; Tarnani M; Ferrara F; Pinto A
Am J Hematol; 2006 Aug; 81(8):598-602. PubMed ID: 16823816
[TBL] [Abstract][Full Text] [Related]
11. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
[TBL] [Abstract][Full Text] [Related]
12. Rituximab in autoimmune hematologic diseases: not just a matter of B cells.
Stasi R
Semin Hematol; 2010 Apr; 47(2):170-9. PubMed ID: 20350664
[TBL] [Abstract][Full Text] [Related]
13. Rituximab for the treatment of childhood chronic idiopathic thrombocytopenic purpura and hemophilia with inhibitors.
Franchini M; Zaffanello M; Veneri D; Lippi G
Pediatr Blood Cancer; 2007 Jul; 49(1):6-10. PubMed ID: 17311349
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura.
Cooper N; Stasi R; Cunningham-Rundles S; Feuerstein MA; Leonard JP; Amadori S; Bussel JB
Br J Haematol; 2004 Apr; 125(2):232-9. PubMed ID: 15059147
[TBL] [Abstract][Full Text] [Related]
15. The efficacy of rituximab in the treatment of inhibitor-associated hemostatic disorders.
Franchini M; Veneri D; Lippi G; Stenner R
Thromb Haemost; 2006 Aug; 96(2):119-25. PubMed ID: 16894452
[TBL] [Abstract][Full Text] [Related]
16. B-cell compartment as the selective target for the treatment of immune thrombocytopenias.
Zaja F; Vianelli N; Sperotto A; De Vita S; Iacona I; Zaccaria A; Masolini P; Tomadini V; Tani M; Molinari AL; Baccarani M; Fanin R
Haematologica; 2003 May; 88(5):538-46. PubMed ID: 12745273
[TBL] [Abstract][Full Text] [Related]
17. Rituximab: an anti-CD20 antibody for the treatment of chronic refractory immune thrombocytopenic purpura.
Aggarwal A; Catlett JP
South Med J; 2002 Oct; 95(10):1209-12. PubMed ID: 12425512
[TBL] [Abstract][Full Text] [Related]
18. A review of the current use of rituximab in autoimmune diseases.
Gürcan HM; Keskin DB; Stern JN; Nitzberg MA; Shekhani H; Ahmed AR
Int Immunopharmacol; 2009 Jan; 9(1):10-25. PubMed ID: 19000786
[TBL] [Abstract][Full Text] [Related]
19. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening autoimmune haemolytic anaemia in a patient with systemic lupus erythematosus.
Perrotta S; Locatelli F; La Manna A; Cennamo L; De Stefano P; Nobili B
Br J Haematol; 2002 Feb; 116(2):465-7. PubMed ID: 11841453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
